Moreover, HER2-amplified breast cancers display increased sensitivity to certain chemotherapeutic agents, such as doxorubicin, increased resistance to certain hormonal agents, such as tamoxifen, and increased propensity to metastasize to the brain, lungs, and liver [66,67]. Here, ERBB2 is linked to breast cancer.